DNA repair signature is associated with anthracycline response in triple negative breast cancer patients

Breast Cancer Research and Treatment

Volumn 123, Issue 1, 2010, Pages 189-196

  Rodriguez, A A ^a   Makris, A ^b   Wu, M F ^a   Rimawi, M ^a   Froehlich, A ^a   Dave, B ^a   Hilsenbeck, S G ^a   Chamness, G C ^a   Lewis, M T ^a   Dobrolecki, L E ^a   Jain, D ^c   Sahoo, S ^c   Osborne, C K ^a   Chang, J C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Anthracycline sensitivity; BRCA1; Breast cancer; DNA repair; Gene expression signatures

Indexed keywords

ANTHRACYCLINE; BRCA1 PROTEIN; CHECKPOINT KINASE 1; CYCLOPHOSPHAMIDE; DNA; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FANCONI ANEMIA GROUP A PROTEIN; FLUOROURACIL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROGESTERONE RECEPTOR; RAD51 PROTEIN; RNA; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; TAXOID;

ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA MICROARRAY; DNA REPAIR; DRUG RESPONSE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADJUVANT THERAPY; AREA UNDER THE CURVE; BIOSYNTHESIS; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); DRUG RESISTANCE; FEMALE; GENETICS; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; HUMANS; NEOADJUVANT THERAPY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE; TAXOIDS;

EID: 77955770116     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0983-z     Document Type: Article

References (41)

1. LA Carey EC Dees L Sawyer L Gatti DT Moore F Collichio,, et al. 2007 The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 8 2329 2334 10.1158/1078-0432.CCR-06-1109 1:CAS:528:DC%2BD2sXkt1enur0%3D 17438091 (Pubitemid 46698581)
2. von Minckwitz G KM, Kümmel S, Fasching P, Eiermann W, Blohmer J-U, Costa SD, Sibylle L, Dietmar V, Untch M (2008) Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane ± trastuzumab containing chemotherapy. SABCS Abstract 792008
3. T Sorlie R Tibshirani J Parker T Hastie JS Marron A Nobel,, et al. 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100 14 8418 8423 10.1073/pnas.0932692100 1:CAS:528:DC%2BD3sXlsFGntLk%3D 12829800 (Pubitemid 36842560)
4. C Bernstein H Bernstein CM Payne H Garewal 2002 DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis Mutat Res 511 2 145 178 10.1016/S1383-5742(02)00009-1 1:CAS:528:DC%2BD38XktFKnsbk%3D 12052432 (Pubitemid 34621252)
5. P Tassone MT Di Martino M Ventura A Pietragalla I Cucinotto T Calimeri,, et al. 2009 Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo Cancer Biol Ther 8 7 648 653 10.4161/cbt.8.7.7968 1:CAS:528:DC%2BD1MXotFSjsb0%3D 19333003
6. MM Murray PB Mullan DP Harkin 2007 Role played by BRCA1 in transcriptional regulation in response to therapy Biochem Soc Trans 35 5 1342 1346 10.1042/BST0351342 1:CAS:528:DC%2BD2sXht1eqsr7N 17956347 (Pubitemid 350206496)
7. RD Kennedy JE Quinn PB Mullan PG Johnston DP Harkin 2004 The role of BRCA1 in the cellular response to chemotherapy J Natl Cancer Inst 96 22 1659 1668 10.1093/jnci/djh312 1:CAS:528:DC%2BD2cXhtVSqsrzO 15547178 (Pubitemid 39585635)
8. P Tassone P Tagliaferri A Perricelli S Blotta B Quaresima ML Martelli,, et al. 2003 BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells Br J Cancer 88 8 1285 1291 10.1038/sj.bjc.6600859 1:CAS:528:DC%2BD3sXivFShsr0%3D 12698198 (Pubitemid 36606348)
9. Delaloge S, Bidard F, El Masmoudi Y, Bressac de Paillerets B, Caron O, Bourgier C, Garbay J, Spielmann M, André F. BRCA1 germ-line mutation: Predictive of sensitivity to anthracyclin alkylating agents regimens but not to taxanes? J Clin Oncol. Abstract 5742008 May 20, 26
10. PO Chappuis J Goffin N Wong C Perret P Ghadirian PN Tonin,, et al. 2002 A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer J Med Genet 39 8 608 610 10.1136/jmg.39.8.608 1:STN:280: DC%2BD38vgvVKrug%3D%3D 12161606
11. A Hubert B Mali T Hamburger Y Rottenberg B Uziely T Peretz,, et al. 2009 Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer Fam Cancer 8 173 177 10.1007/s10689-008-9223-7 1:CAS:528:DC%2BD1MXptVGqsb4%3D 19016350
12. T Byrski T Huzarski R Dent J Gronwald D Zuziak C Cybulski,, et al. 2009 Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients Breast Cancer Res Treat 115 359 363 10.1007/s10549-008-0128-9 1:CAS:528:DC%2BD1MXmsVGjsrs%3D 18649131
13. T Byrski J Gronwald T Huzarski E Grzybowska M Budryk M Stawicka,, et al. 2008 Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers Breast Cancer Res Treat 108 2 289 296 10.1007/s10549-007-9600-1 1:CAS:528:DC%2BD1cXitleqsb8%3D 17492376 (Pubitemid 351311366)
14. NC Turner JS Reis-Filho AM Russell RJ Springall K Ryder D Steele,, et al. 2007 BRCA1 dysfunction in sporadic basal-like breast cancer Oncogene 26 14 2126 2132 10.1038/sj.onc.1210014 1:CAS:528:DC%2BD2sXjsFSiu7c%3D 17016441 (Pubitemid 46514749)
15. CR James JE Quinn PB Mullan PG Johnston DP Harkin 2007 BRCA1, a potential predictive biomarker in the treatment of breast cancer Oncologist 12 2 142 150 10.1634/theoncologist.12-2-142 1:CAS:528:DC%2BD2sXjtFChsLo%3D 17296808
16. NC Turner JS Reis-Filho 2006 Basal-like breast cancer and the BRCA1 phenotype Oncogene 25 43 5846 5853 10.1038/sj.onc.1209876 1:CAS:528: DC%2BD28XhtVSgurjO 16998499 (Pubitemid 44453440)
17. LC Brody 2005 Treating cancer by targeting a weakness N Engl J Med 353 9 949 950 10.1056/NEJMcibr052331 1:CAS:528:DC%2BD2MXpsFChu7w%3D 16135843 (Pubitemid 41247939)
18. N Turner A Tutt A Ashworth 2004 Hallmarks of 'BRCAness' in sporadic cancers Nat Rev Cancer 4 10 814 819 10.1038/nrc1457 1:CAS:528: DC%2BD2cXos1ymu7g%3D 15510162 (Pubitemid 39331153)
19. CR Mueller CD Roskelley 2003 Regulation of BRCA1 expression and its relationship to sporadic breast cancer Breast Cancer Res 5 1 45 52 10.1186/bcr557 1:CAS:528:DC%2BD3sXjtlCisr4%3D 12559046 (Pubitemid 36553579)
20. MJ van de Vijver YD He LJ van' t Veer H Dai AA Hart DW Voskuil,, et al. 2002 A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 25 1999 2009 10.1056/NEJMoa021967 12490681 (Pubitemid 35461656)
21. SK Mohsin HL Weiss MC Gutierrez GC Chamness R Schiff MP Digiovanna,, et al. 2005 Neoadjuvant trastuzumab induces apoptosis in primary breast cancers J Clin Oncol 23 11 2460 2468 10.1200/JCO.2005.00.661 1:CAS:528: DC%2BD2MXjvVyktL4%3D 15710948 (Pubitemid 47050836)
22. P Farmer H Bonnefoi P Anderle D Cameron P Wirapati V Becette,, et al. 2009 A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer Nat Med 15 1 68 74 10.1038/nm.1908 1:CAS:528:DC%2BD1MXhtVyjsQ%3D%3D 19122658
23. H Bonnefoi A Potti M Delorenzi L Mauriac M Campone M Tubiana-Hulin,, et al. 2007 Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial Lancet Oncol 8 12 1071 1078 10.1016/S1470-2045(07)70345-5 1:CAS:528:DC%2BD2sXhsVWjur%2FK 18024211 (Pubitemid 350182953)
24. JC Chang EC Wooten A Tsimelzon SG Hilsenbeck MC Gutierrez R Elledge,, et al. 2003 Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer Lancet 362 9381 362 369 10.1016/S0140-6736(03)14023-8 1:CAS:528:DC%2BD3sXlvFGnsLo%3D 12907009 (Pubitemid 36957839)
25. JC Chang EC Wooten A Tsimelzon SG Hilsenbeck MC Gutierrez YL Tham,, et al. 2005 Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients J Clin Oncol 23 6 1169 1177 10.1200/JCO.2005.03.156 1:CAS:528:DC%2BD2MXitl2gur0%3D 15718313 (Pubitemid 46202273)
26. RW Martin BJ Orelli M Yamazoe AJ Minn S Takeda DK Bishop 2007 RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors Cancer Res 67 20 9658 9665 10.1158/0008-5472.CAN-07-0290 1:CAS:528:DC%2BD2sXhtFOnsLfN 17942895 (Pubitemid 47621212)
27. M Cronin M Pho D Dutta JC Stephans S Shak MC Kiefer,, et al. 2004 Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay Am J Pathol 164 1 35 42 1:CAS:528:DC%2BD2cXlsVChtA%3D%3D 14695316
28. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A,, et al (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3(7):RESEARCH0034
29. C Liedtke C Mazouni KR Hess F Andre A Tordai JA Mejia,, et al. 2008 Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 8 1275 1281 10.1200/JCO.2007.14. 4147 18250347
30. PJ Wysocki K Korski K Lamperska J Zaluski A Mackiewicz 2008 Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations Med Sci Monit 14 7 SC7 SC10 1:CAS:528:DC%2BD1cXhtFKisrrL 18591931
31. P Tassone S Blotta C Palmieri S Masciari B Quaresima M Montagna,, et al. 2005 Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents Int J Oncol 26 5 1257 1263 1:CAS:528:DC%2BD2MXktVOrsrs%3D 15809716
32. PM Gilmore N McCabe JE Quinn RD Kennedy JJ Gorski HN Andrews,, et al. 2004 BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3 Cancer Res 64 12 4148 4154 10.1158/0008-5472.CAN-03-4080 1:CAS:528:DC%2BD2cXkvFWls7s%3D 15205325 (Pubitemid 38802417)
33. AE Teschendorff A Miremadi SE Pinder IO Ellis C Caldas 2007 An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer Genome Biol 8 8 R157 10.1186/gb-2007-8-8-r157 17683518 (Pubitemid 351891480)
34. B Kreike M van Kouwenhove H Horlings B Weigelt H Peterse H Bartelink,, et al. 2007 Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas Breast Cancer Res 9 5 R65 10.1186/bcr1771 17910759 (Pubitemid 350187481)
35. BP Schneider EP Winer WD Foulkes J Garber CM Perou A Richardson,, et al. 2008 Triple-negative breast cancer: risk factors to potential targets Clin Cancer Res 14 24 8010 8018 10.1158/1078-0432.CCR-08-1208 1:CAS:528: DC%2BD1cXhsV2it73F 19088017
36. MK Sgagias KU Wagner B Hamik S Stoeger R Spieker LJ Huber,, et al. 2004 Brca1-deficient murine mammary epithelial cells have increased sensitivity to CDDP and MMS Cell Cycle 3 11 1451 1456 1:CAS:528:DC%2BD2MXhtleku7fJ 15492509
37. A Ashworth 2008 A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair J Clin Oncol 26 22 3785 3790 10.1200/JCO.2008.16.0812 1:CAS:528:DC%2BD1cXhtVGjs7rL 18591545
38. H Farmer N McCabe CJ Lord AN Tutt DA Johnson TB Richardson,, et al. 2005 Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 7035 917 921 10.1038/nature03445 1:CAS:528:DC%2BD2MXjtFOmsrc%3D 15829967 (Pubitemid 40559006)
39. PC Fong DS Boss TA Yap A Tutt P Wu M Mergui-Roelvink,, et al. 2009 Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2 123 134 10.1056/NEJMoa0900212 1:CAS:528:DC%2BD1MXosVKrtrw%3D 19553641
40. O'Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, Rocha C, Ossovskaya V, Sherman B, Bradley C (2009) Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol. Abstract 32009; 27
41. LV Abruzzo KY Lee A Fuller A Silverman MJ Keating LJ Medeiros,, et al. 2005 Validation of oligonucleotide microarray data using microfluidic low-density arrays: a new statistical method to normalize real-time RT-PCR data Biotechniques 38 5 785 792 10.2144/05385MT01 1:CAS:528:DC%2BD2MXkt1Whsbw%3D 15945375